Cargando…

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Sci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diener, Hans-Christoph, Tassorelli, Cristina, Dodick, David W, Silberstein, Stephen D, Lipton, Richard B, Ashina, Messoud, Becker, Werner J, Ferrari, Michel D, Goadsby, Peter J, Pozo-Rosich, Patricia, Wang, Shuu-Jiun, Mandrekar, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501455/ https://www.ncbi.nlm.nih.gov/pubmed/30806518 http://dx.doi.org/10.1177/0333102419828967

Ejemplares similares

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
por: Diener, Hans Christoph, et al.
Publicado: (2021)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
por: Saper, Joel R, et al.
Publicado: (2011)

Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study
por: Ashina, Håkan, et al.
Publicado: (2020)

Non-headache symptoms in migraine patients
por: Chen, Ping-Kun, et al.
Publicado: (2018)

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review
por: Dodick, David W., et al.
Publicado: (2022)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Debate: Are cluster headache and migraine distinct headache disorders?
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2022)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Migraine and cluster headache – the common link
por: Vollesen, Anne Luise, et al.
Publicado: (2018)

The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2022)

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

O012. Intra-variability of the characteristics of migraine attacks
por: Viana, Michele, et al.
Publicado: (2015)

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials
por: Ashina, Messoud, et al.
Publicado: (2021)

EHMTI-0111. Intra-variability of migraine attacks features
por: Viana, M, et al.
Publicado: (2014)

A history of International Headache Society grants and their impact on headache careers
por: Puledda, Francesca, et al.
Publicado: (2022)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Calcitonin Gene-Related Peptide in Tension-Type Headache
por: Ashina, Messoud
Publicado: (2001)

Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
por: Lipton, Richard B., et al.
Publicado: (2022)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Chronic headache and nitric oxide inhibitors
por: Ashina, Messoud, et al.
Publicado: (2001)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study
por: Viana, Michele, et al.
Publicado: (2020)

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study
por: Silberstein, Stephen D., et al.
Publicado: (2016)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
por: Aurora, SK, et al.
Publicado: (2014)

European headache federation consensus on technical investigation for primary headache disorders
por: Mitsikostas, D. D., et al.
Publicado: (2016)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

The migraine postdrome: An electronic diary study
por: Giffin, Nicola J., et al.
Publicado: (2016)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
por: Sacco, Simona, et al.
Publicado: (2022)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rsuchqtjpg6bpg2j24v51j1eth